Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Abstract Text:

Andrew Feigin,Michael G Kaplitt,Chengke Tang,Tanya Lin,Paul Mattis,Vijay Dhawan,Matthew J During,David Eidelberg,Andrew Feigin,Michael G Kaplitt,Chengke Tang,Tanya Lin,Paul Mattis,Vijay Dhawan,Matthew J During,David Eidelberg,Andrew Feigin,Michael G Kaplitt,Chengke Tang,Tanya Lin,Paul Mattis,Vijay Dhawan,Matthew J During,David Eidelberg,

Parkinson's disease (PD) is characterized by elevated expression of an abnormal metabolic brain network that is reduced by clinically effective treatment. We used fluorodeoxyglucose (FDG) positron emission tomography (PET) to determine the basis for motor improvement in 12 PD patients receiving unilateral subthalamic nucleus (STN) infusion of an adenoassociated virus vector expressing glutamic acid decarboxylase (AAV-GAD). After gene therapy, we observed significant reductions in thalamic metabolism on the operated side as well as concurrent metabolic increases in ipsilateral motor and premotor cortical regions. Abnormal elevations in the activity of metabolic networks associated with motor and cognitive functioning in PD patients were evident at baseline. The activity of the motor-related network declined after surgery and persisted at 1 year. These network changes correlated with improved clinical disability ratings. By contrast, the activity of the cognition-related network did not change after gene transfer. This suggests that modulation of abnormal network activity underlies the clinical outcome observed after unilateral STN AAV-GAD gene therapy. Network biomarkers may be used as physiological assays in early-phase trials of experimental therapies for PD and other neurodegenerative disease.

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Publishing Authors By Initials

A Feigin,MG Kaplitt,C Tang,T Lin,P Mattis,V Dhawan,MJ During,D Eidelberg,A Feigin,MG Kaplitt,C Tang,T Lin,P Mattis,V Dhawan,MJ During,D Eidelberg,A Feigin,MG Kaplitt,C Tang,T Lin,P Mattis,V Dhawan,MJ During,D Eidelberg,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Proceedings of the National Academy of Sciences of

VOLUME: 104

Page Numbers: 19559-64

Journal Abbreviation: Proc. Natl. Acad. Sci. U.S.A.

ISSN: 1091-6490

DAY: 27

MONTH: 11

YEAR: 2007

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7505876

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

AFFILIATION: Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, 350 Community Drive, Manhasset, NY 11030.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Proc Natl Acad Sci U S A

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease Related Publications

• Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.
• Abnormal metabolic networks in atypical parkinsonism.
• An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.
• Callosal and non-callosal connexions between the sensory-motor cortices in cat and monkey.
• Cerebral glucose metabolism and D(2)/D (3) receptor availability in young adults with cannabis dependence measured with positron emission tomography.
• Changes in network activity with the progression of Parkinson's disease.
• Correlates of movement initiation and velocity in Parkinson's disease: A longitudinal PET study.
• Development of electrical activity in the cerebral cortex of the newborn rat.
• Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.
• Dopaminergic suppression of brain deactivation responses during sequence learning.
• Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.
• Functional imaging of sequence learning in Parkinson's disease.
• Gene transfer therapy for neurodegenerative disorders.
• Habituation of somatosensory evoked potentials in the lemniscal system of the cat.
• Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease.
• Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study.
• Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease.
• Metabolic brain networks associated with cognitive function in Parkinson's disease.
• Metabolic correlates of subthalamic nucleus activity in Parkinson's disease.
• Microstructural white matter changes in primary torsion dystonia.
• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.
• Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease.
• Spectrum analysis of residual EEG changes following post-natal x-irradiation in rats.
• Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.
• Thalamic metabolism and symptom onset in preclinical Huntington's disease.
• The assessment of neurological systems with functional imaging.
• Thermoelectric freezing stage for serial brain sectioning.
• [Not Available.]
• [Not Available.]
• [Treatment of pain in neoplastic diseases.]